In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Can Ron Zwanziger Do It Again?

Executive Summary

In the past two years, Inverness Medical Innovations has paid a total of roughly $500 million to buy five rapid point-of-care (POCT) diagnostic testing businesses, which now lie at the heart of its effort to expand in the POCT realm. These have laid the ground work for four subsequent transactions and related financings, all aimed at making Inverness a world leader in women's health and pregnancy testing. But what's of interest isn't so much the women's health play per se as the company's management tream, which has twice before built up POCT companies, then sold them for significant premiums.

You may also be interested in...



Inverness Buys Bulk

Inverness Medical Innovations, a point-of-care diagnostics company, made a splash with its $1.6 billion acquisition of Biosite. But the purchase was merely the latest step in a long-time strategy of growing through acquisition.

Inverness Buys Bulk

Inverness Medical Innovations, a point-of-care diagnostics company, made a splash with its $1.6 billion acquisition of Biosite. But the purchase was merely the latest step in a long-time strategy of growing through acquisition.

Wake-up Calls in IVD

Inverness Medical Innovations and Beckman Coulter are currently in a bidding war for Biosite and its point of care BNP test. The fight is just one example of the demand for innovative diagnostic test content. The recent upswing in IVD deal-making, along with renewed VC interest in diagnostics, suggests that the area's potential to drive health care innovation by directing therapy more efficiently is finally being recognized.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV002015

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel